Altitrade Partners Member Level Saturday, 03/20/21 10:43:47 AM
Re: docj post# 3414 0
Post #
3415
of 3423
Perhaps even more than that.

"Novel anti-anginal therapies are few and far between. There has been only one anti-anginal drug with a novel mechanism of action approved by the FDA in the past half-century (Gilead’s Ranexa), which was acquired one year following FDA approval for $1.4 billion."

https://www.nytimes.com/2009/03/13/business/13biotech.html

<<"The drug will be worth over $800 million on a buyout.">>